Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.79% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 4.65% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 0% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.79% of any dividend from JUBLPHARMA should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
The stock shows a strong positive 3-month return but negative 1- and 6-month returns, with the 50-day average still below the 200-day and the price some distance from its 52-week high. This indicates a rebound within a broader sideways-to-weak structure rather than a confirmed trend.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.